Navigation Links
Resverlogix Completes Dosing for ASSERT Trial
Date:5/12/2010

Completion occurs 5 months ahead of schedule

TSX Exchange Symbol: RVX

CALGARY, May 12 /PRNewswire-FirstCall/ - Resverlogix is pleased to announce that the Phase 2 ASSERT clinical trial for its lead drug, RVX-208, a small molecule therapy for the treatment of atherosclerosis has now completed dosing. "The completion of dosing for our Phase 2 ASSERT trial, five months ahead of schedule and without any alterations to the dose levels of the three drug receiving cohorts, is another major step forward in the development of this important cardiovascular drug. Our clinical team and our collaborators at the Cleveland Clinic will now spend the next few months assessing the study results to best plan for upcoming trials. The swift completion of the ASSERT study further allows us to make better assessments in identifying optimal dosing regimens moving forward," explained Donald J. McCaffrey, President and CEO of Resverlogix. McCaffrey continued, "Earlier studies have indicated that the drug worked best in those subjects with low HDL, therefore we will further assess if RVX-208 has a targeted effect in this high risk cardiovascular disease population. The rapid enrollment and dosing success for this trial was in large part due to having one organized Internal Review Board (IRB) for all 40 sites involved in the trial."

The ASSERT trial is a randomized, double-blind, placebo-controlled, multi-centered US study for 13 weeks of administration of RVX-208, which has enrolled 299 patients with stable coronary artery disease for a period of 13 weeks. The primary endpoint of the study is to determine if RVX-208 will produce an increase in plasma Apolipoprotein A-I (ApoA-I) levels compared to placebo group after three months of dosing. Other objectives are to examine the safety and tolerability of RVX-208 and to com
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
2. Resverlogix is Presenting at IAS HDL Workshop
3. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
4. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
5. Resverlogix Share Option Extension
6. Resverlogix Notice of Conference Call & Webcast
7. /C O R R E C T I O N from Source -- Resverlogix Corp./
8. Industry Leaders Select Resverlogixs RVX-208
9. Resverlogixs Lead Drug Featured in Key Scientific Publication
10. Jan Gray Joins Resverlogix Board of Directors
11. Resverlogix Notice of Conference Call & Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... (PRWEB) April 30, 2015 Clinovo ... 2015 PharmaSUG Annual Conference held in Orlando, FL ... Staffing Solutions along with Leslie Kolman, Manager of Staffing ... latest Clinovo news at Booth #17. , “We ... Conference again this year”, Says Trisha Heredia, Senior Director ...
(Date:4/29/2015)... USA (PRWEB) April 29, 2015 ... sensing, and imaging on the East Coast, reaffirmed its ... managers, researchers, applications developers, and industry suppliers to meet ... imaging for multiple applications. , The event included 55 ... commercial and scientific sensing and imaging -- and an ...
(Date:4/29/2015)... N.J. , April 29, 2015 Cambrex Corporation ... results will be released on Friday, May 1, 2015 before ... The Company will host a conference call to ... When: , Friday, May 1, ... , 1-888-468-2440 for U.S.1-719-325-2454 for International  Passcode:  7993632 ...
(Date:4/29/2015)... Gene therapy can clip out genetic material ... gene in human cardiac cells, according to a study led ... of Medicine at Mount Sinai. The study is published in ... mutations, the small random, changes in the genetic code making ... seen in patients with heart failure,” says Roger J. Hajjar, ...
Breaking Biology Technology:Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 2Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 3SPIE DSS provides venue for collaboration vital to research, applications advances 2SPIE DSS provides venue for collaboration vital to research, applications advances 3SPIE DSS provides venue for collaboration vital to research, applications advances 4Gene Therapy Clips Out Heart Failure Causing Gene Mutations 2Gene Therapy Clips Out Heart Failure Causing Gene Mutations 3Gene Therapy Clips Out Heart Failure Causing Gene Mutations 4
... Jan. 24 Quintiles,Transnational Corp. today announced the ... support the company,s continued,growth under the leadership of ... and the management team. Gillings and global private,investment ... the lead,investors in Quintiles, with 3i also becoming ...
... of chemistry and biochemistry at The University of Texas ... Chemistry jointly with Professor William Moerner of Stanford University. ... Professor Yuli Tamir, was given to the two scientists ... single-molecule spectroscopy and imaging. , The $100,000 prize will ...
... ... - Non-GAAP Diluted EPS Up 15%, GAAP Diluted ... VARI) today reported first quarter 2008 revenues of $237.4,million, representing an increase ... year 2007. The increase was broad-based,with growth in sales of products for ...
Cached Biology Technology:Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i 2Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i 3Varian, Inc. Reports First Quarter 2008 Results 2Varian, Inc. Reports First Quarter 2008 Results 3Varian, Inc. Reports First Quarter 2008 Results 4Varian, Inc. Reports First Quarter 2008 Results 5Varian, Inc. Reports First Quarter 2008 Results 6Varian, Inc. Reports First Quarter 2008 Results 7Varian, Inc. Reports First Quarter 2008 Results 8Varian, Inc. Reports First Quarter 2008 Results 9Varian, Inc. Reports First Quarter 2008 Results 10Varian, Inc. Reports First Quarter 2008 Results 11Varian, Inc. Reports First Quarter 2008 Results 12Varian, Inc. Reports First Quarter 2008 Results 13Varian, Inc. Reports First Quarter 2008 Results 14Varian, Inc. Reports First Quarter 2008 Results 15Varian, Inc. Reports First Quarter 2008 Results 16Varian, Inc. Reports First Quarter 2008 Results 17Varian, Inc. Reports First Quarter 2008 Results 18
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
(Date:3/23/2015)... March 23, 2015   HOYOS Labs , a ... today announced that the Company will demonstrate multiple biometrics-based ... and consumers at Connect:ID on March 23 through 25, ... Labs will highlight the IEEE Biometric Open Protocol Standard; ... and enterprise access control system. BOPS was invented by ...
(Date:3/20/2015)... OXFORD, Conn. , March 20, 2015 ... "Company"), a biometric authentication company focused on the growing ... Wocket® smart wallet is one of the products featured ... today, March 20th at 11:00 PM EST on the ... travels to Las Vegas , site ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... Medical Center clinical researchers will present findings about a ... Francisco at the Interscience Conference on Antimicrobial Agents and ... research team is presenting data in two poster presentations ... killing 99.9 percent of infectious airborne germs. Findings from ...
... to newly placed sod may result in nutrient runoff into ... to apply fertilizer and what kind is the best for ... team of scientists from Texas A&M AgriLife Research: Dr. Jacqui ... Ben Wherley, assistant professor of turfgrass science and ecology; Dr. ...
... principal cause of global warming? A new study by two ... keeps sea urchins in check will in turn allow kelp forests to ... amount of CO 2 from the atmosphere than if it were ... theory is outlined in a paper released online today (September 7, 2012) ...
Cached Biology News:Research finds novel airborne germ-killing oral spray effective in fighting colds and flu 2Turf study to monitor runoff, establish fertilizer management practices 2UC Santa Cruz study shows how sea otters can reduce CO2 in the atmosphere 2
B-FABP (FL-132)...
... Phosphatase ( l-PPase) is ... with activity towards phosphorylated ... residues. It is the ... the ORF221 open reading ...
... Innovative HL-2000 HybriLinker combines the benefits of a ... self-contained, space saving unit. , ... Laboratory allows crosslinking ,and hybridization at one location ... HL-2000 operate independently of each other , ...
... traps a wide variety of solvent vapors that ... glass condensation flask (GCF400) allows for the collection ... easy draining. Rapid cooling time minimizes waiting period., ... quick solvent changes , -50?C ...
Biology Products: